Drug intelligence / Profile preview

GMS-P07

Development stage: Preclinical
Lead developer: Gifted Molecular Science
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

GMS-P07 is an antisense oligonucleotide (ASO) candidate being developed by Gifted Molecular Science for the treatment of human metapneumovirus (HMPV) infection. The drug is designed using the company's proprietary Druggable-PNA (D-PNA) platform, which chemically incorporates a cationic lipid segment into a peptide nucleic acid (PNA) nucleobase to enhance cell membrane affinity, cell permeability, and binding affinity. GMS-P07 is designed to target HMPV genetic material, thereby inhibiting viral replication and gene expression.

Targets

hMPV (Human metapneumovirus)

Beyond the preview

Go deeper on GMS-P07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GMS-P07.